Compare Moderna, Inc. (MRNA) vs TeraWulf Inc (WULF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs TeraWulf Inc — how do they compare? Moderna, Inc. trades at $225 (market cap $78.65B), while TeraWulf Inc trades at $13.77 (market cap $6.81B). The key difference: Moderna, Inc. is far larger — about 11.5× TeraWulf Inc's market cap, and Moderna, Inc. is trading nearer its 52-week high, TeraWulf Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and TeraWulf Inc for 17 Days on average.
| MRNA | WULF | |
|---|---|---|
Market Cap | $78.65B | $6.81B |
Volume | 37,373,437 | 45,841,998 |
Sector | Health | Financials |
52-Week High | $203.46 | $28.98 |
52-Week Low | $22.36 | $10.99 |
Typical Hold Time | 59 Days | 17 Days |
Enterprise Value | $74.80B | $9.43B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $197.00, up 0.26% on the day, with technical indicators showing a bullish trend and strong momentum. The stock has rallied over 500% in 2026, driven by positive clinical updates for its cancer vaccine pipeline and inclusion in the Nasdaq-100 index effective October 9, 2026. However, fundamentals remain challenging with revenue declining from $18.9B in 2022 to $1.9B in 2025 and negative net income margins exceeding 140%.
While technical momentum and pipeline optimism support near-term upside, valuation appears stretched with P/S of 35.08 and negative profitability metrics. Key risks include execution on non-COVID products, competitive pressure, and sustainability of recent gains. Analyst consensus is cautious with only 28% buy ratings and $115.70 price target suggesting significant downside from current levels.
WULF trades at $13.65, down 5.21% today, amid a bearish technical signal and volatile AI infrastructure sector sentiment. The company reported a net loss of $661.42 million in 2025 with a negative net income margin of -392.64%, while revenue was $168.46 million. Recent news highlights its pivot to AI data centers, with stock movements influenced by sector-wide trends and analyst coverage.
Outlook remains speculative with high valuation ratios (P/S 35.73, P/B 46.24) and persistent losses posing risks, but 100% analyst buy ratings and a $34.92 consensus price target suggest long-term growth potential from AI hosting contracts. Key risks include execution challenges and competitive pressures in the evolving AI infrastructure space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About TeraWulf Inc
TeraWulf develops, owns, and operates fully integrated digital infrastructure powered by predominantly zero-carbon energy. It utilizes a hybrid business model that combines industrial-scale Bitcoin mining with high-performance computing (HPC) and AI hosting, leveraging sustainable power sources like nuclear and hydroelectric to deliver low-cost, energy-efficient data center solutions.
Read more on WULF →
